Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States.
Joseph C AhnMarie LauzonMichael LuuMazen NoureddinWalid AyoubAlexander KuoVinay SundaramKambiz KosariNicholas NissenJun GongAndrew HendifarLewis R RobertsGhassan K Abou-AlfaAmit G SingalJu Dong YangPublished in: Hepatology (Baltimore, Md.) (2022)
Immunotherapy was associated with improved OS compared with chemotherapy in advanced HCC. There are significant disparities in early access to immunotherapy, likely due to differential access to clinical trials and experimental therapies. A comprehensive approach to monitoring and eliminating racial-ethnic disparities in the management of advanced HCC is urgently needed.